{{Rsnum
|rsid=10061997
|Gene=SLC36A3
|Chromosome=5
|position=151279426
|Orientation=plus
|GMAF=0.2608
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=SLC36A3
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 3.1 | 13.8 | 83.1
| HCB | 2.2 | 33.3 | 64.4
| JPT | 6.7 | 35.6 | 57.8
| YRI | 33.9 | 50.0 | 16.1
| ASW | 0.0 | 0.0 | 0.0
| CHB | 2.2 | 33.3 | 64.4
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs10061997
|Name_s=
|Gene_s=SLC36A3
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. In combination, rs278917, rs10061997, rs12190776, and rs9730073 were all significant predictors of etoposide IC50, and accounted for 40% of the etoposide IC50 variation in Yorubans. Study size: 89. Study population/ethnicity: 89 Yorubans. Significance metric(s): p = 0.00002. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109512
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs10061997
|overall_frequency_n=34
|overall_frequency_d=128
|overall_frequency=0.265625
|n_genomes=24
|n_genomes_annotated=0
|n_haplomes=28
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}